Travere Therapeutics, Inc. (TVTX) shares jumped 31.57 percent to $40.42, gaining $9.72 on Monday, after the company received U.S. Food and Drug Administration approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis.
The stock is currently trading at $40.42, up from its previous close of $30.70 on the Nasdaq. It opened at $41.53 and has traded in a range of $39.90 to $42.50 during the session, with volume reaching 6.94 million shares compared to an average of 1.52 million shares.
The approval marks FILSPARI as the first and only FDA-approved treatment for FSGS, expanding its use beyond IgA nephropathy. Clinical data showed significant reductions in proteinuria, supporting its potential as a key therapy for this rare kidney disease. The 52-week range for the stock is $13.88 to $42.50.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.